Jacques E Rossouw

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Estrogen therapy and coronary-artery calcification
    JoAnn E Manson
    Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02215, USA
    N Engl J Med 356:2591-602. 2007
  2. ncbi request reprint Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial
    Jacques E Rossouw
    Division of Women s Health Initiative, National Heart, Lung, and Blood Institute, 6705 Rockledge Dr, One Rockledge Ctr, Suite 300, Bethesda, MD 20817
    JAMA 288:321-33. 2002
  3. pmc Relationships of coronary heart disease with 27-hydroxycholesterol, low-density lipoprotein cholesterol, and menopausal hormone therapy
    Jacques E Rossouw
    National Heart, Lung, and Blood Institute, Rockledge 2 Bldg, Room 9192, Bethesda, MD 20892, USA
    Circulation 126:1577-86. 2012
  4. pmc Lessons learned from the Women's Health Initiative trials of menopausal hormone therapy
    Jacques E Rossouw
    National Heart, Lung, and Blood Institute, Bethesda, Maryland 20892, USA
    Obstet Gynecol 121:172-6. 2013
  5. ncbi request reprint Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause
    Jacques E Rossouw
    Women s Health Initiative Branch, National Heart, Lung, and Blood Institute, Bethesda, MD 20892, USA
    JAMA 297:1465-77. 2007
  6. pmc Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the women's health initiative trials of hormone therapy
    Jacques E Rossouw
    Women s Health Initiative Branch, Division of Prevention and Population Sciences, National Heart, Lung, and Blood Institute, 6701 Rockledge Dr, Rockledge 2 Bldg, Ste 10018, Bethesda, MD 20892, USA
    Arch Intern Med 168:2245-53. 2008
  7. pmc Tissue factor pathway inhibitor, activated protein C resistance, and risk of ischemic stroke due to postmenopausal hormone therapy
    Jacques E Rossouw
    National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 9192, Bethesda, MD 20892, USA
    Stroke 43:952-7. 2012
  8. ncbi request reprint Implications of recent clinical trials of postmenopausal hormone therapy for management of cardiovascular disease
    Jacques E Rossouw
    Women s Health Initiative, National Heart, Lung, and Blood Institute, Rockledge 2, Room 8106, 6701 Rockledge Drive, Bethesda, MD 20892, USA
    Ann N Y Acad Sci 1089:444-53. 2006
  9. ncbi request reprint Hormones, genetic factors, and gender differences in cardiovascular disease
    Jacques E Rossouw
    Women s Health Initiative, National Heart, Lung and Blood Institute, 1 Rockledge Center, Suite 300, 6705 Rockledge Drive, Bethesda, MD 20892 7966, USA
    Cardiovasc Res 53:550-7. 2002
  10. ncbi request reprint The hormone therapy dilemma: women respond
    Erica S Breslau
    Applied Cancer Screening Research Branch, Behavioral Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute in Bethesda, Maryland, USA
    J Am Med Womens Assoc 58:33-43. 2003

Detail Information

Publications34

  1. ncbi request reprint Estrogen therapy and coronary-artery calcification
    JoAnn E Manson
    Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02215, USA
    N Engl J Med 356:2591-602. 2007
    ..We examined the relationship between estrogen therapy and coronary-artery calcium in the context of a randomized clinical trial...
  2. ncbi request reprint Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial
    Jacques E Rossouw
    Division of Women s Health Initiative, National Heart, Lung, and Blood Institute, 6705 Rockledge Dr, One Rockledge Ctr, Suite 300, Bethesda, MD 20817
    JAMA 288:321-33. 2002
    ..Despite decades of accumulated observational evidence, the balance of risks and benefits for hormone use in healthy postmenopausal women remains uncertain...
  3. pmc Relationships of coronary heart disease with 27-hydroxycholesterol, low-density lipoprotein cholesterol, and menopausal hormone therapy
    Jacques E Rossouw
    National Heart, Lung, and Blood Institute, Rockledge 2 Bldg, Room 9192, Bethesda, MD 20892, USA
    Circulation 126:1577-86. 2012
    ..The endogenous estrogen receptor antagonist 27-hydroxycholesterol (27OHC) is correlated with LDLC levels and may block the beneficial effects of estrogen on the cardiovascular system...
  4. pmc Lessons learned from the Women's Health Initiative trials of menopausal hormone therapy
    Jacques E Rossouw
    National Heart, Lung, and Blood Institute, Bethesda, Maryland 20892, USA
    Obstet Gynecol 121:172-6. 2013
    ..Menopausal HT is not suitable for long-term prevention of CHD given risks of stroke, venous thromboembolism, and breast cancer (for estrogen plus progestin therapy) found in both clinical trials and in observational studies...
  5. ncbi request reprint Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause
    Jacques E Rossouw
    Women s Health Initiative Branch, National Heart, Lung, and Blood Institute, Bethesda, MD 20892, USA
    JAMA 297:1465-77. 2007
    ..The timing of initiation of hormone therapy may influence its effect on cardiovascular disease...
  6. pmc Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the women's health initiative trials of hormone therapy
    Jacques E Rossouw
    Women s Health Initiative Branch, Division of Prevention and Population Sciences, National Heart, Lung, and Blood Institute, 6701 Rockledge Dr, Rockledge 2 Bldg, Ste 10018, Bethesda, MD 20892, USA
    Arch Intern Med 168:2245-53. 2008
    ..Clinical trials of postmenopausal hormone therapy (HT) have shown increased risk of coronary heart disease (CHD) in the first few years after initiation of therapy and no overall benefit...
  7. pmc Tissue factor pathway inhibitor, activated protein C resistance, and risk of ischemic stroke due to postmenopausal hormone therapy
    Jacques E Rossouw
    National Heart, Lung, and Blood Institute, 6701 Rockledge Drive, Room 9192, Bethesda, MD 20892, USA
    Stroke 43:952-7. 2012
    ....
  8. ncbi request reprint Implications of recent clinical trials of postmenopausal hormone therapy for management of cardiovascular disease
    Jacques E Rossouw
    Women s Health Initiative, National Heart, Lung, and Blood Institute, Rockledge 2, Room 8106, 6701 Rockledge Drive, Bethesda, MD 20892, USA
    Ann N Y Acad Sci 1089:444-53. 2006
    ....
  9. ncbi request reprint Hormones, genetic factors, and gender differences in cardiovascular disease
    Jacques E Rossouw
    Women s Health Initiative, National Heart, Lung and Blood Institute, 1 Rockledge Center, Suite 300, 6705 Rockledge Drive, Bethesda, MD 20892 7966, USA
    Cardiovasc Res 53:550-7. 2002
  10. ncbi request reprint The hormone therapy dilemma: women respond
    Erica S Breslau
    Applied Cancer Screening Research Branch, Behavioral Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute in Bethesda, Maryland, USA
    J Am Med Womens Assoc 58:33-43. 2003
    ..In the wake of the premature end of the Women's Health Initiative (WHI) study, we sought to assess women's knowledge of and attitudes about hormone therapy (HT) study findings and to appraise women's responses and intentions...
  11. ncbi request reprint Effect of postmenopausal hormone therapy on cardiovascular risk
    Jacques E Rossouw
    Women s Health Initiative, National Heart, Lung, and Blood Institute, 1 Rockledge Drive, Bethesda, MD 20892 7966, USA
    J Hypertens Suppl 20:S62-5. 2002
    ....
  12. ncbi request reprint Coronary heart disease in menopausal women: implications of primary and secondary prevention trials of hormones
    Jacques E Rossouw
    National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892 7966, USA
    Maturitas 51:51-63. 2005
    ..Their use for other indications (menopausal symptoms, osteoporosis) needs to be tempered by the risk for cardiovascular disease (CVD)...
  13. ncbi request reprint Hormones for coronary disease-full circle
    Jacques E Rossouw
    US Department of Health and Human Services, National Heart, Lung, and Blood Institute, Bethesda, MD 20892, USA
    Lancet 360:1996-7. 2002
  14. ncbi request reprint Trials for menopausal women
    Jacques E Rossouw
    National Heart, Lung and Blood Institute, Bethesda, USA
    J Br Menopause Soc 10:6. 2004
  15. ncbi request reprint Monitoring and reporting of the Women's Health Initiative randomized hormone therapy trials
    Garnet L Anderson
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
    Clin Trials 4:207-17. 2007
    ..The results contravened prevailing wisdom and a large body of literature regarding benefits of menopausal hormone therapy. The results and their interpretation have been the subject of considerable debate...
  16. pmc Estrogen plus progestin therapy and breast cancer in recently postmenopausal women
    Ross L Prentice
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Am J Epidemiol 167:1207-16. 2008
    ..64 (95% confidence interval: 1.00, 2.68) over a 5-year period of use and 2.19 (95% confidence interval: 1.56, 3.08) over a 10-year period of use...
  17. pmc Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study
    Ross L Prentice
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA 98109 1024, USA
    Am J Epidemiol 167:1407-15. 2008
    ....
  18. pmc Usefulness of baseline lipids and C-reactive protein in women receiving menopausal hormone therapy as predictors of treatment-related coronary events
    Paul F Bray
    Cardeza Foundation for Hematologic Research and Jefferson Medical College, Philadelphia, Pennsylvania, USA
    Am J Cardiol 101:1599-1605. 2008
    ..However, women with favorable lipid levels, especially LDL/HDL cholesterol ratio <2.5, did not have increased risk of coronary heart disease with CEE with or without MPA irrespective of hs-CRP...
  19. pmc Lipoprotein particle concentrations may explain the absence of coronary protection in the women's health initiative hormone trials
    Judith Hsia
    Department of Medicine, George Washington University, Washington, DC, USA
    Arterioscler Thromb Vasc Biol 28:1666-71. 2008
    ..In an effort to explain this finding, we examined lipoprotein particle concentrations and their interactions with hormone therapy in a case-control substudy...
  20. ncbi request reprint Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study
    Aruna D Pradhan
    Center for Cardiovascular Disease Prevention, Division of Preventive Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02215 1204, USA
    JAMA 288:980-7. 2002
    ..Several inflammatory biomarkers, including CRP, are associated with increased cardiovascular risk. However, whether the effect of HRT on CRP represents a clinical hazard is unknown...
  21. ncbi request reprint Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial
    Barbara V Howard
    MedStar Research Institute Howard University, Washington, DC, USA
    JAMA 295:655-66. 2006
    ..Multiple epidemiologic studies and some trials have linked diet with cardiovascular disease (CVD) prevention, but long-term intervention data are needed...
  22. ncbi request reprint Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial
    Sylvia Wassertheil-Smoller
    Department of Epidemiology and Social Medicine, Albert Einstein College of Medicine, Bronx, NY 10461, USA
    JAMA 289:2673-84. 2003
    ..The Women's Health Initiative (WHI) trial of estrogen plus progestin was stopped early because of adverse effects, including an increased risk of stroke in the estrogen plus progestin group...
  23. ncbi request reprint Evolving practice patterns and attitudes toward hormone therapy of obstetrician-gynecologists
    Michael L Power
    Department of Research, American College of Obstetricians and Gynecologists, Washington, DC 20024, USA
    Menopause 14:20-8. 2007
    ..The objective of this study was to examine the opinions and prescribing practices of obstetrician-gynecologists regarding hormone therapy (HT) and the results from the Women's Health Initiative...
  24. ncbi request reprint Women's Ischemic Syndrome Evaluation: current status and future research directions: report of the National Heart, Lung and Blood Institute workshop: October 2-4, 2002 : Section 4: lessons from hormone replacement trials
    David D Waters
    Circulation 109:e53-5. 2004
  25. ncbi request reprint Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial
    Garnet L Anderson
    Fred Hutchinson Cancer Research Center, Seattle, Wash 98109 1024, USA
    JAMA 291:1701-12. 2004
    ..Despite decades of use and considerable research, the role of estrogen alone in preventing chronic diseases in postmenopausal women remains uncertain...
  26. ncbi request reprint Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial
    Ross L Prentice
    Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Wash 98109, USA
    JAMA 295:629-42. 2006
    ..The hypothesis that a low-fat dietary pattern can reduce breast cancer risk has existed for decades but has never been tested in a controlled intervention trial...
  27. ncbi request reprint Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial
    Shirley A A Beresford
    Department of Epidemiology, University of Washington, Seattle, WA 98195 7236, USA
    JAMA 295:643-54. 2006
    ..Observational studies and polyp recurrence trials are not conclusive regarding the effects of a low-fat dietary pattern on risk of colorectal cancer, necessitating a primary prevention trial...
  28. ncbi request reprint Estrogen plus progestin and the risk of coronary heart disease
    JoAnn E Manson
    Division of Preventive Medicine, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02215, USA
    N Engl J Med 349:523-34. 2003
    ..In this report, we provide the final results with regard to estrogen plus progestin and CHD from the Women's Health Initiative (WHI)...
  29. ncbi request reprint Effects of conjugated equine estrogen on stroke in the Women's Health Initiative
    Susan L Hendrix
    Department of Obstetrics and Gynecology, Wayne State University School of Medicine Hutzel Women s Hospital, Detroit, MI, USA
    Circulation 113:2425-34. 2006
    ..This report provides a thorough analysis of the stroke finding using the final results from the completed trial database...
  30. ncbi request reprint Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin
    Garnet L Anderson
    WHI Clinical Coordinating Center, Public Health Sciences Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, M3 A410, P O Box 19024, Seattle, WA 98109 1024, United States
    Maturitas 55:103-15. 2006
    ..To assess the extent to which prior hormone therapy modifies the breast cancer risk found with estrogen plus progestin (E+P) in the Women's Health Initiative (WHI) randomized trial...
  31. pmc Oophorectomy, hormone therapy, and subclinical coronary artery disease in women with hysterectomy: the Women's Health Initiative coronary artery calcium study
    Matthew A Allison
    University of California San Diego, La Jolla, CA, USA
    Menopause 15:639-47. 2008
    ..In this study, we aimed to determine the associations between coronary artery calcium (CAC) and hysterectomy, oophorectomy, and hormone therapy use with a focus on the duration of menopause for which there was no hormone therapy use...
  32. ncbi request reprint Bone mineral density of American Indian and Alaska Native women compared with non-Hispanic white women: results from the Women's Health Initiative Study
    Nina S Wampler
    Noqsi Research, Pine, CO 80470, USA
    Menopause 12:536-44. 2005
    ..To compare bone mineral density (BMD) of American Indian/Alaska Native (AI/AN) women with that of non-Hispanic white women...
  33. ncbi request reprint Baseline associations between postmenopausal hormone therapy and inflammatory, haemostatic, and lipid biomarkers of coronary heart disease. The Women's Health Initiative Observational Study
    Robert D Langer
    Department of Family and Preventive Medicine, University of California, San Diego, 9500 Gilman Drive, MC 0978, La Jolla, CA 92093 0978, USA
    Thromb Haemost 93:1108-16. 2005
    ..Some associations differed between women with and without incident CHD, especially for EP, where inflammatory and thrombotic markers were higher in cases. These associations remain speculative pending confirmation in randomized trials...
  34. ncbi request reprint The Women's Health Initiative recruitment methods and results
    Jennifer Hays
    From the WHI Clinical Center, Baylor College of Medicine, Houston, TX 77030, USA
    Ann Epidemiol 13:S18-77. 2003